Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03237130
Other study ID # CTRadiomics-LMesophagus-BNSF
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 15, 2017
Est. completion date May 15, 2020

Study information

Verified date January 2021
Source Beijing Cancer Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study proposes to establish a CT radiomics-based prediction model for identifying metastasis lymph nodes in esophageal cancer.


Description:

This study proposes to establish an image feature extraction and selection method for identifying lymph node metastasis of esophageal cancer.The study will consider the relationship between the main lesion and the suspected lymph node, extract association characteristics in order to improve the sensitivity and specificity of the CT radiomics-based prediction model for identifying metastasis lymph nodes. The study includes the construction of CT radiomics-based prediction model and the validation of the prediction model.


Recruitment information / eligibility

Status Completed
Enrollment 133
Est. completion date May 15, 2020
Est. primary completion date November 7, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - pathologically proven esophageal cancer - scheduled to preoperative enhanced chest CT and undergo surgery - sign the patient informed consent Exclusion Criteria: - failed to receive preoperative enhanced chest CT or undergo surgery - inavailable pathological results for local lymph node status - inquality of CT images for feature extraction - patient quit

Study Design


Intervention

Procedure:
preoperative enhanced chest CT examination
Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary pathological local lymph node status pathological lymph node status is defined as lymph node metastasis exist or not Pathologic evaluation will be performed for each patient within 1 week after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Completed NCT00201747 - Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer Phase 2
Recruiting NCT06036563 - Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
Not yet recruiting NCT05023928 - Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer Phase 1
Recruiting NCT03941626 - Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies Phase 1/Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Recruiting NCT02988921 - MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy N/A
Terminated NCT02797405 - Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay N/A
Completed NCT02979691 - Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01 Phase 2/Phase 3
Recruiting NCT03347630 - Pre-operative MRI of Esophagus Cancer N/A
Completed NCT00193141 - Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer Phase 2
Recruiting NCT05626309 - Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer N/A
Completed NCT05615129 - Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
Recruiting NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Phase 2
Terminated NCT03108885 - Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
Recruiting NCT04046575 - Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer Phase 1
Recruiting NCT06126406 - Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors Phase 1
Completed NCT03467529 - Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study
Completed NCT02552121 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT02001623 - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Phase 1/Phase 2